enGene Therapeutics Inc. (ENGN)
| Market Cap | 487.01M +138.8% |
| Revenue (ttm) | n/a |
| Net Income | -122.44M |
| EPS | -2.22 |
| Shares Out | 66.99M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 155,174 |
| Open | 7.05 |
| Previous Close | 7.04 |
| Day's Range | 7.00 - 7.36 |
| 52-Week Range | 2.65 - 12.25 |
| Beta | -0.05 |
| Analysts | Buy |
| Price Target | 21.08 (+189.96%) |
| Earnings Date | Jun 11, 2026 |
About ENGN
enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings Inc. and changed its name to enGene Therapeutics Inc. in April 2026. enGene Therapeutics Inc. is based... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for ENGN stock is "Buy." The 12-month stock price target is $21.08, which is an increase of 189.96% from the latest price.
News
enGene Announces Name Change to enGene Therapeutics Inc.
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (formerly, enGene Holdings Inc.) (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, is pleas...
enGene Therapeutics Transcript: The Citizens Life Sciences Conference 2026
NMIBC treatment is shifting from radical surgery to more tolerable, effective therapies, with detalimogene showing strong efficacy and ease of use for community urologists. Key data updates are expected in Q2 and later this year, supporting a potential 2027 approval.
enGene Therapeutics Transcript: Barclays 28th Annual Global Healthcare Conference
Detalimogene, a non-viral gene therapy for NMIBC, is advancing through pivotal trials with strong regulatory support and a focus on community urologists. The product's ease of use, competitive efficacy, and favorable tolerability are expected to drive adoption as the market shifts toward sequencing therapies.
enGene Therapeutics Transcript: Leerink Global Healthcare Conference 2026
Major protocol amendments and improved execution have driven higher response rates in the pivotal cohort, with 12-month data expected later this year. Regulatory engagement is strong, aided by RMAT and CDRP designations, and the product is positioned for broad adoption in community urology practices due to its ease of use and favorable economics.
enGene Reports First Quarter 2026 Financial Results and Provides Business Update
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced its financial results for the...
enGene Therapeutics Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference
Detalimogene voraplasmid is advancing as a non-viral gene therapy for NMIBC, showing strong efficacy and tolerability in pivotal trials, with a six-month CR rate of 62%. The product offers significant advantages in ease of use, manufacturing, and cost, with a BLA filing planned for late 2024 and potential launch in 2027.
enGene to Participate in Upcoming Investor Conferences
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene”), a clinical-stage, non-viral genetic medicines company, today announced that management will participate in the foll...
enGene Therapeutics Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026
Detalimogene is positioned for strong adoption in community urology due to its efficacy, best-in-class tolerability, and ease of use. The pivotal LEGEND study is fully enrolled, with top-line data and regulatory filing expected in the second half of the year, supported by robust FDA engagement and a flexible pricing strategy.
enGene to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene”), a clinical-stage, non-viral genetic medicines company, today announced that Ron Cooper, President and Chief Executi...
enGene Announces Expanded $125 Million Debt Facility with Hercules Capital, Inc.
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced that it has entered into an a...
enGene Reports Full Year 2025 Financial Results and Provides Business Update
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced its financial results for the...
enGene Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference
A novel non-viral gene therapy platform is advancing a lead product for NMIBC, showing strong efficacy, safety, and ease of use in clinical trials. Regulatory designations and protocol improvements have enhanced outcomes, with a data update expected in 2026 and a launch targeted for 2027.
enGene's Detalimogene Selected for FDA Manufacturing Pilot Program to Support Manufacturing Readiness
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced that the U.S. Food and Drug...
enGene to Present at the Piper Sandler 37th Annual Healthcare Conference
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene”), a clinical-stage, non-viral genetic medicines company, today announced that Alex Nichols, Ph.D., Chief Strategy and...
enGene Therapeutics Transcript: Jefferies London Healthcare Conference 2025
Detalimogene voraplasmid, a non-viral gene therapy for NMIBC, shows strong efficacy and tolerability, with a six-month CR rate of 62% and low adverse events. Positioned for community urologists, it offers simple logistics and is on track for regulatory filing next year.
enGene Announces Pricing of $130 Million Public Offering of Common Shares and Pre-Funded Warrants
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced the pricing of its previously...
enGene Announces Proposed Public Offering of Common Shares
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced that it has commenced an unde...
enGene Therapeutics Transcript: Stifel 2025 Healthcare Conference
Non-viral gene therapy for NMIBC shows a 63% complete response rate and strong tolerability, matching or exceeding other approved products. Its ease of use and integration into community urology practices, along with a robust manufacturing and IP position, support its competitive outlook.
enGene Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference
Datolimogene hayemab shows strong efficacy and best-in-class tolerability in NMIBC, with pivotal trial enrollment completed and protocol amendments improving outcomes. Manufacturing and financial positions are robust, supporting U.S. commercialization and further pipeline expansion.
EnGene Encouraged By Promising Response Rates In Bladder Cancer Trial
enGene Holdings Inc. (NASDAQ:ENGN) stock is edging higher on Tuesday, with a session volume of 18.62 million compared to an average volume of 266.85 thousand, as per data from Benzinga Pro.
enGene Therapeutics Transcript: Study Update
Detalimogene's amended LEGEND study protocol led to a 63% anytime and 62% six-month CR rate in high-risk BCG unresponsive NMIBC, with a strong safety and tolerability profile. Ease of use and minimal operational burden make it attractive for community practices. Most 12-month data will mature in late 2026.
Detalimogene Demonstrates Improved Complete Response Rate of 62% at 6 Months
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today reported additional preliminary data ...
enGene to Host Conference Call to Provide Update on Pivotal Cohort of LEGEND Trial
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced that it will host a confere...
enGene Named a BioSpace 2026 Best Places to Work Winner
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (“enGene” or the “Company”) (Nasdaq: ENGN), a clinical-stage, non-viral genetic medicines company, today announced that BioSpace has named the ...
enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today reported the grant of inducement equity...